KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.

Market Cap	$721.30M	P/E Ratio	N/A
52W High	$17.28	52W Low	$7.30
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-3.2%	52W Position	58.1%
Overall Score	53	Value Score	40
Quality Score	--	Technical Score	66

EPS Current Est	$-2.72	EPS Next Est	$-2.41
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	KALV	$13.10	+0.61%	989.31K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	KALV	$13.10	+0.6%	989.31K
3
4
5
6

KALV

KALV

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get KalVista Pharmaceuticals Inc. Data in Excel

Get KalVista Pharmaceuticals Inc. Data in Excel